http://adisinsight.springer.com/drugs/800037736
Patent Information
In October 2014, the US Patent and Trademark Office (USPTO) granted Neos a US Patent No. 8 840 924 that covering its proprietary XR-oral disintegrating tablet technology, RDIM™ .
In September 2014, Neos announced settlement of all pending litigation with Shire related to amfetamine extended-release orally disintegrating tablet. The companies entered into a license agreement which provides Neos license to the US Patent Nos. RE 42 096, 41 148 and 6 913 768, to develop and market amfetamine extended-release orally disintegrating tablet. Shire will be eligible for a royalty from the sales of the drug until the patents expire. In April 2013, Shire filed lawsuit against Neos asserting that Neos infringed the US Patent Nos. RE 42 096 and 41 148 and stopped Neos from filing its NDA under section 505(b)(2) with the US FDA .
In May 2014, Neos announced that it had been issued US Patent No. 8 709 491 by the USPTO. The patent provides IP protection for the company's amphetamine ADHD products, including its extended release amphetamine oral disintegrating tablet and extended release amphetamine liquid suspension, until June 2032 .
